Milestone Pharmaceuticals (MIST) Income from Continuing Operations (2018 - 2022)
Milestone Pharmaceuticals (MIST) posted Income from Continuing Operations of 15030000.0 for Q3 2022, up 10.57% on a QoQ basis from 16806000.0 in Q2 2022, and down 5.66% year-over-year from 15931576.01 in Q3 2021.
Milestone Pharmaceuticals (MIST) Income from Continuing Operations (2018 - 2022) Analysis & Trends
Milestone Pharmaceuticals' Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 15030000.0 for Q3 2022.
- Quarterly Income from Continuing Operations fell 5.66% year-over-year to 15030000.0 in Q3 2022, while the trailing twelve-month figure through Sep 2022 was 62945000.0 (down 81.74% YoY) and the FY2021 annual result came in at 42853000.0, up 14.24% from the prior year.
- Income from Continuing Operations was 15030000.0 for Q3 2022 at Milestone Pharmaceuticals, up from 16806000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 770000.0 in Q2 2021 and bottomed at 18288000.0 in Q4 2019.
- A 5-year average of 11281777.78 and a median of 12672500.0 in 2019 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations soared 105.93% — and 2022, when it tumbled 2282.6%.
- Milestone Pharmaceuticals' Income from Continuing Operations stood at 9717000.0 in 2018, then tumbled by 88.21% to 18288000.0 in 2019, then jumped by 52.61% to 8666000.0 in 2020, then tumbled by 94.83% to 16884000.0 in 2021, then grew by 10.98% to 15030000.0 in 2022.
- Business Quant data shows MIST's Income from Continuing Operations at 15030000.0 in Q3 2022, 16806000.0 in Q2 2022, and 16884000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Milestone Pharmaceuticals | 156.34 Mn | -27.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -15.03 Mn |
| Jun 30, 2022 | -16.81 Mn |
| Dec 31, 2021 | -16.88 Mn |
| Sep 30, 2021 | -14.23 Mn |
| Jun 30, 2021 | 770,000.00 |
| Mar 31, 2021 | -12.51 Mn |
| Dec 31, 2020 | -8.67 Mn |
| Sep 30, 2020 | -11.98 Mn |
| Jun 30, 2020 | -12.98 Mn |
| Mar 31, 2020 | -16.34 Mn |
| Dec 31, 2019 | -18.29 Mn |
| Sep 30, 2019 | -12.83 Mn |
| Jun 30, 2019 | -13.66 Mn |
| Mar 31, 2019 | -10.45 Mn |
| Dec 31, 2018 | -9.72 Mn |
| Sep 30, 2018 | -5.70 Mn |
| Jun 30, 2018 | -3.59 Mn |
| Mar 31, 2018 | -4.18 Mn |